Patient-derived lung cancer organoids for the selection of therapeutic options in an ALK-rearranged tumor

Background: ALK rearrangements are key targets in non-small-cell lung cancer (NSCLC). Unfortunately, the optimal sequential strategy of ALK-tyrosine kinase inhibitors (TKI) remains to be defined. Testing drug sensitivity in patient derived organoids (PDOs) could support a rational drug selection in this setting. Conclusions: We present clinical evidence that PDOs are an alternative tool in oncogenic addicted tumors helping to guide treatment decisions and increasing a more personalized sequential treatment approach. READ ARTICLE

Journal of Clinical Oncology DOI:10.1200/JCO.2021.39.15_suppl.e21014

Authors: Beatriz Jimenez Munarriz, Zahra Dantes, Javier De Castro, Paloma Navarro, Monica Yagüe, Arantzazu Barquin, Juan Francisco Rodriguez-Moreno, Elena Sevillano, Sergio Ruiz, Anabel del Barrio, Gema García Ledo, Miriam Dorta, Ana Collazo Lorduy, Emiliano Calvo, Jesús García-Donas, Sandra Serrano, Apoorva Manjunath, Luciana Ferreira, Barbara Hefel, Jordi Remon

Conference PaperKirk SmithMay 28, 2021Patient-derived lung cancer, organoid, therapeutic options, ALK-rearranged tumor

What Is the Standard First-Line Treatment for Advanced Non-Small Cell Lung Cancer?

The initial treatment regimens for advanced non-small cell lung cancer (NSCLC) have drastically evolved over the last 15 years with the rapid development of improved genomic sequencing technologies and the emergence of immune checkpoint inhibitors. Highly active oral kinase inhibitors are now approved for several molecularly defined subsets of NSCLC, including those harboring alterations in the EGFR, ALK, ROS1, BRAF, MET, RET, and NTRK genes, although acquired resistance to these targeted therapies remains a significant clinical challenge. In lung cancers lacking targetable mutations, programmed death 1/programmed death ligand 1 immune checkpoint inhibitors, used alone or in combination with cytotoxic T-lymphocyte-associated protein 4 inhibitors and/or cytotoxic chemotherapy, have led to meaningful improvements in overall survival. With many therapeutic options available to patients, here we review the recommended frontline treatment regimens for advanced NSCLC with and without targetable genomic drivers. READ ARTICLE

Cancer (Journal) DOI: 10.1097/PPO.0000000000000489

Authors: Ricciuti B, Awad MM.

Review PaperKirk SmithDecember 1, 2020ALK, therapeutic options